Notch Signaling in Developmental and Tumor Angiogenesis

Genes and Cancer

Volumn 2, Issue 12, 2011, Pages 1106-1116

  Kofler, Natalie M ^a   Shawber, Carrie J ^a   Kangsamaksin, Thaned ^a   Reed, Hasina Outtz ^a   Galatioto, Josephine ^a   Kitajewski, Jan ^a  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

Dll4; Notch; sprouting angiogenesis; VEGF

Indexed keywords

NOTCH RECEPTOR;

ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; ENDOTHELIUM CELL; HUMAN; MACROPHAGE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84868618772     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911423030     Document Type: Article

References (129)

1. Yochem J,Weston K,Greenwald I.The Caenorhabditis elegans lin-12 gene encodes a transmembrane protein with overall similarity to Drosophila Notch.Nature. 1988;335 (6190): 547-50.
2. Greenwald I.LIN-12/Notch signaling: lessons from worms and flies.Genes Dev. 1998;12 (12): 1751-62.
3. Kopan R,Ilagan MX.The canonical Notch signaling pathway: unfolding the activation mechanism.Cell. 2009;137 (2): 216-33.
4. Kovall RA,Blacklow SC.Mechanistic insights into Notch receptor signaling from structural and biochemical studies.Curr Top Dev Biol. 2010;92:31-71.
5. Shawber CJ,Das I,Francisco E, et al.Notch signaling in primary endothelial cells.Ann N Y Acad Sci. 2003;995:162-70.
6. Davis RL,Turner DL.Vertebrate hairy and Enhancer of split related proteins: transcriptional repressors regulating cellular differentiation and embryonic patterning.Oncogene. 2001;20 (58): 8342-57.
7. Nakagawa O,McFadden DG,Nakagawa M, et al.Members of the HRT family of basic helix-loop-helix proteins act as transcriptional repressors downstream of Notch signaling.Proc Natl Acad Sci U S A. 2000;97 (25): 13655-60.
8. Del Amo FF,Smith DE,Swiatek PJ, et al.Expression pattern of Motch, a mouse homolog of Drosophila Notch, suggests an important role in early postimplantation mouse development.Development. 1992;115 (3): 737-44.
9. Uyttendaele H,Marazzi G,Wu G, et al.Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene.Development. 1996;122 (7): 2251-9.
10. Beckers J,Clark A,Wunsch K, et al.Expression of the mouse Delta1 gene during organogenesis and fetal development.Mech Dev. 1999;84 (1-2): 165-8.
11. Shutter JR,Scully S,Fan W, et al.Dll4, a novel Notch ligand expressed in arterial endothelium.Genes Dev. 2000;14 (11): 1313-8.
12. Mailhos C,Modlich U,Lewis J, et al.Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis.Differentiation. 2001;69:135-44.
13. Zimrin AB,Pepper MS,McMahon GA, et al.An antisense oligonucleotide to the notch ligand jagged enhances fibroblast growth factor-induced angiogenesis in vitro.J Biol Chem. 1996;271 (51): 32499-502.
14. Thurston G,Noguera-Troise I,Yancopoulos GD.The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth.Nat Rev Cancer. 2007;7 (5): 327-31.
15. Siekmann AF,Covassin L,Lawson ND.Modulation of VEGF signalling output by the Notch pathway.Bioessays. 2008;30 (4): 303-13.
16. Phng LK,Potente M,Leslie JD, et al.Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis.Dev Cell. 2009;16 (1): 70-82.
17. Carmeliet P,Ferreira V,Breier G, et al.Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele.Nature. 1996;380 (6573): 435-9.
18. Ferrara N,Carver-Moore K,Chen H, et al.Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene.Nature. 1996;380 (6573): 439-42.
19. Gale NW,Dominguez MG,Noguera I, et al.Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development.Proc Natl Acad Sci U S A. 2004;101 (45): 15949-54.
20. Krebs LT,Shutter JR,Tanigaki K, et al.Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants.Genes Dev. 2004;18 (20): 2469-73.
21. Suchting S,Freitas C,Le Noble F, et al.The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching.Proc Natl Acad Sci U S A. 2007;104 (9): 3225-30.
22. Krebs LT,Xue Y,Norton CR, et al.Notch signaling is essential for vascular morphogenesis in mice.Genes Dev. 2000;14 (11): 1343-52.
23. Fischer A,Schumacher N,Maier M, et al.The Notch target genes Hey1 and Hey2 are required for embryonic vascular development.Genes Dev. 2004;18 (8): 901-11.
24. Limbourg A,Ploom M,Elligsen D, et al.Notch ligand Delta-like 1 is essential for postnatal arteriogenesis.Circ Res. 2007;100 (3): 363-71.
25. Sorensen I,Adams RH,Gossler A.DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteries.Blood. 2009;113 (22): 5680-8.
26. Uyttendaele H,Ho J,Rossant J, et al.Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium.Proc Natl Acad Sci U S A. 2001;98 (10): 5643-8.
27. Krebs LT,Starling C,Chervonsky AV, et al.Notch1 activation in mice causes arteriovenous malformations phenocopied by ephrinB2 and EphB4 mutants.Genesis. 2010;48 (3): 146-50.
28. Taylor KL,Henderson AM,Hughes CC.Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression.Microvasc Res. 2002;64 (3): 372-83.
29. Harrington LS,Sainson RC,Williams CK, et al.Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells.Microvasc Res. 2008;75 (2): 144-54.
30. Funahashi Y,Shawber CJ,Vorontchikhina M, et al.Notch regulates the angiogenic response via induction of VEGFR-1.J Angiogenes Res. 2010;2 (1): 3.
31. Outtz HH,Wu JK,Wang X, et al.Notch1 deficiency results in decreased inflammation during wound healing and regulates vascular endothelial growth factor receptor-1 and inflammatory cytokine expression in macrophages.J Immunol. 2010;185 (7): 4363-73.
32. Shawber CJ,Funahashi Y,Francisco E, et al.Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression.J Clin Invest. 2007;117 (11): 3369-82.
33. Duarte A,Hirashima M,Benedito R, et al.Dosage-sensitive requirement for mouse Dll4 in artery development.Genes Dev. 2004;18 (20): 2474-8.
34. Iso T,Maeno T,Oike Y, et al.Dll4-selective Notch signaling induces ephrinB2 gene expression in endothelial cells.Biochem Biophys Res Commun. 2006;341 (3): 708-14.
35. Carlson TR,Yan Y,Wu X, et al.Endothelial expression of constitutively active Notch4 elicits reversible arteriovenous malformations in adult mice.Proc Natl Acad Sci U S A. 2005;102 (28): 9884-9.
36. Trindade A,Kumar SR,Scehnet JS, et al.Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos.Blood. 2008;112 (5): 1720-9.
37. Shibuya M.Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis.Angiogenesis. 2006;9 (4): 225-30.
38. Tammela T,Zarkada G,Wallgard E, et al.Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.Nature. 2008;454 (7204): 656-60.
39. Risau W,Flamme I.Vasculogenesis.Annu Rev Cell Dev Biol. 1995;11:73-91.
40. Herbert SP,Huisken J,Kim TN, et al.Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation.Science. 2009;326 (5950): 294-8.
41. Kim YH,Hu H,Guevara-Gallardo S, et al.Artery and vein size is balanced by Notch and ephrin B2/EphB4 during angiogenesis.Development. 2008;135 (22): 3755-64.
42. Hellstrom M,Phng LK,Hofmann JJ, et al.Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis.Nature. 2007;445 (7129): 776-80.
43. Lobov IB,Renard RA,Papadopoulos N, et al.Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting.Proc Natl Acad Sci U S A. 2007;104 (9): 3219-24.
44. Gerhardt H,Golding M,Fruttiger M, et al.VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia.J Cell Biol. 2003;161 (6): 1163-77.
45. Benedito R,Roca C,Sorensen I, et al.The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis.Cell. 2009;137 (6): 1124-35.
46. Liu ZJ,Shirakawa T,Li Y, et al.Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis.Mol Cell Biol. 2003;23 (1): 14-25.
47. Patel NS,Li JL,Generali D, et al.Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function.Cancer Res. 2005;65 (19): 8690-7.
48. Jakobsson L,Franco CA,Bentley K, et al.Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting.Nat Cell Biol. 2010;12 (10): 943-53.
49. Guarani V,Deflorian G,Franco CA, et al.Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase.Nature. 2011;473 (7346): 234-8.
50. Benjamin LE,Hemo I,Keshet E.A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF.Development. 1998;125 (9): 1591-8.
51. Armulik A,Abramsson A,Betsholtz C.Endothelial/pericyte interactions.Circ Res. 2005;97 (6): 512-23.
52. Villa N,Walker L,Lindsell CE, et al.Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels.Mech Dev. 2001;108:161-4.
53. Hofmann JJ,Luisa Iruela-Arispe M.Notch expression patterns in the retina: An eye on receptor-ligand distribution during angiogenesis.Gene Expr Patterns. 2007;7 (4): 461-70.
54. High FA,Lu MM,Pear WS, et al.Endothelial expression of the Notch ligand Jagged1 is required for vascular smooth muscle development.Proc Natl Acad Sci U S A. 2008;105 (6): 1955-9.
55. Liu H,Kennard S,Lilly B.NOTCH3 expression is induced in mural cells through an autoregulatory loop that requires endothelial-expressed JAGGED1.Circ Res. 2009;104 (4): 466-75.
56. Liu H,Zhang W,Kennard S, et al.Notch3 is critical for proper angiogenesis and mural cell investment.Circ Res. 2010;107 (7): 860-70.
57. Domenga V,Fardoux P,Lacombe P, et al.Notch3 is required for arterial identity and maturation of vascular smooth muscle cells.Genes Dev. 2004;18 (22): 2730-5.
58. Joutel A,Andreux F,Gaulis S, et al.The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients.J Clin Invest. 2000;105 (5): 597-605.
59. Joutel A,Corpechot C,Ducros A, et al.Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia.Nature. 1996;383 (6602): 707-10.
60. Leveen P,Pekny M,Gebre-Medhin S, et al.Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities.Genes Dev. 1994;8 (16): 1875-87.
61. Soriano P.Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice.Genes Dev. 1994;8 (16): 1888-96.
62. Jin S,Hansson EM,Tikka S, et al.Notch signaling regulates platelet-derived growth factor receptor-beta expression in vascular smooth muscle cells.Circ Res. 2008;102 (12): 1483-91.
63. Campos AH,Wang W,Pollman MJ, et al.Determinants of Notch-3 receptor expression and signaling in vascular smooth muscle cells: implications in cell-cycle regulation.Circ Res. 2002;91 (11): 999-1006.
64. Noseda M,McLean G,Niessen K, et al.Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation.Circ Res. 2004;94 (7): 910-7.
65. Noseda M,Fu Y,Niessen K, et al.Smooth Muscle alpha-actin is a direct target of Notch/CSL.Circ Res. 2006;98 (12): 1468-70.
66. Stewart KS,Zhou Z,Zweidler-McKay P, et al.Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation.Blood. 2011;117 (2): 719-26.
67. Schroeder T,Kohlhof H,Rieber N, et al.Notch signaling induces multilineage myeloid differentiation and up-regulates PU.1 expression.J Immunol. 2003;170 (11): 5538-48.
68. Bigas A,Martin DI,Milner LA.Notch1 and Notch2 inhibit myeloid differentiation in response to different cytokines.Mol Cell Biol. 1998;18 (4): 2324-33.
69. Monsalve E,Perez MA,Rubio A, et al.Notch-1 up-regulation and signaling following macrophage activation modulates gene expression patterns known to affect antigen- presenting capacity and cytotoxic activity.J Immunol. 2006;176 (9): 5362-73.
70. Singh N,Phillips RA,Iscove NN, et al.Expression of notch receptors, notch ligands, and fringe genes in hematopoiesis.Exp Hematol. 2000;28 (5): 527-34.
71. Mills CD,Kincaid K,Alt JM, et al.M-1/M-2 macrophages and the Th1/Th2 paradigm.J Immunol. 2000;164 (12): 6166-73.
72. Classen A,Lloberas J,Celada A.Macrophage activation: classical versus alternative.Methods Mol Biol. 2009;531:29-43.
73. Noonan DM,De Lerma Barbaro A,Vannini N, et al.Inflammation, inflammatory cells and angiogenesis: decisions and indecisions.Cancer Metastasis Rev. 2008;27 (1): 31-40.
74. Leibovich SJ,Polverini PJ,Shepard HM, et al.Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha.Nature. 1987;329 (6140): 630-2.
75. Huang SP,Wu MS,Shun CT, et al.Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma.J Biomed Sci. 2004;11 (4): 517-27.
76. Hu X,Chung AY,Wu I, et al.Integrated regulation of Toll-like receptor responses by Notch and interferon-gamma pathways.Immunity. 2008;29 (5): 691-703.
77. Foldi J,Chung AY,Xu H, et al.Autoamplification of Notch signaling in macrophages by TLR-induced and RBP-J-dependent induction of Jagged1.J Immunol. 2010;185 (9): 5023-31.
78. Monsalve E,Ruiz-Garcia A,Baladron V, et al.Notch1 upregulates LPS-induced macrophage activation by increasing NF-kappaB activity.Eur J Immunol. 2009;39 (9): 2556-70.
79. Murakami M,Zheng Y,Hirashima M, et al.VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment.Arterioscler Thromb Vasc Biol. 2008;28 (4): 658-64.
80. Autiero M,Luttun A,Tjwa M, et al.Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders.J Thromb Haemost. 2003;1 (7): 1356-70.
81. Hiratsuka S,Nakamura K,Iwai S, et al.MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis.Cancer Cell. 2002;2 (4): 289-300.
82. Pipp F,Heil M,Issbrucker K, et al.VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism.Circ Res. 2003;92 (4): 378-85.
83. Cursiefen C,Chen L,Borges LP, et al.VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment.J Clin Invest. 2004;113 (7): 1040-50.
84. Mazzieri R,Pucci F,Moi D, et al.Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.Cancer Cell. 2011;19 (4): 512-26.
85. Checchin D,Sennlaub F,Levavasseur E, et al.Potential role of microglia in retinal blood vessel formation.Invest Ophthalmol Vis Sci. 2006;47 (8): 3595-602.
86. Fantin A,Vieira JM,Gestri G, et al.Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction.Blood. 2010;116 (5): 829-40.
87. Kubota Y,Takubo K,Shimizu T, et al.M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis.J Exp Med. 2009;206 (5): 1089-102.
88. Rymo SF,Gerhardt H,Wolfhagen Sand F, et al.A two-way communication between microglial cells and angiogenic sprouts regulates angiogenesis in aortic ring cultures.PLoS One. 2011;6 (1): e15846.
89. Outtz HH,Tattersall IW,Kofler NM, et al.Notch1 controls macrophage recruitment and Notch signaling is activated at sites of endothelial cell anastomosis during retinal angiogenesis in mice.Blood. 2011;:.
90. Imhof BA,Aurrand-Lions M.Angiogenesis and inflammation face off.Nat Med. 2006;12 (2): 171-2.
91. Eming SA,Krieg T,Davidson JM.Inflammation in wound repair: molecular and cellular mechanisms.J Invest Dermatol. 2007;127 (3): 514-25.
92. Wu J,Bresnick EH.Bare rudiments of notch signaling: how receptor levels are regulated.Trends Biochem Sci. 2007;32 (10): 477-85.
93. Leung DW,Cachianes G,Kuang WJ, et al.Vascular endothelial growth factor is a secreted angiogenic mitogen.Science. 1989;246 (4935): 1306-9.
94. Jain RK,Duda DG,Clark JW, et al.Lessons from phase III clinical trials on anti-VEGF therapy for cancer.Nat Clin Pract Oncol. 2006;3 (1): 24-40.
95. Ranganathan P,Weaver KL,Capobianco AJ.Notch signalling in solid tumours: a little bit of everything but not all the time.Nat Rev Cancer. 2011;11 (5): 338-51.
96. DeAngelo DJ,Stone RM,Heaney ML, et al.Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.Blood. 2006;108 (12): 3674-81.
97. Real PJ,Tosello V,Palomero T, et al.Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.Nat Med. 2009;15 (1): 50-8.
98. Noguera-Troise I,Daly C,Papadopoulos NJ, et al.Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.Nature. 2006;444 (7122): 1032-7.
99. Ridgway J,Zhang G,Wu Y, et al.Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis.Nature. 2006;444 (7122): 1083-7.
100. Hoey T,Yen WC,Axelrod F, et al.DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.Cell Stem Cell. 2009;5 (2): 168-77.
101. Yan M,Callahan CA,Beyer JC, et al.Chronic DLL4 blockade induces vascular neoplasms.Nature. 2010;463 (7282): E6-7.
102. Liu Z,Turkoz A,Jackson EN, et al.Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice.J Clin Invest. 2011;121 (2): 800-8.
103. Wu Y,Cain-Hom C,Choy L, et al.Therapeutic antibody targeting of individual Notch receptors.Nature. 2010;464 (7291): 1052-7.
104. Schmid MC,Varner JA.Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation.J Oncol. 2010;2010:201026.
105. Hirschi KK,Rohovsky SA,D'Amore PA.PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate.J Cell Biol. 1998;141 (3): 805-14.
106. Zeng Q,Li S,Chepeha DB, et al.Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling.Cancer Cell. 2005;8 (1): 13-23.
107. Sunderkotter C,Steinbrink K,Goebeler M, et al.Macrophages and angiogenesis.J Leukoc Biol. 1994;55 (3): 410-22.
108. Holash J,Davis S,Papadopoulos N, et al.VEGF-Trap: a VEGF blocker with potent antitumor effects.Proc Natl Acad Sci U S A. 2002;99 (17): 11393-8.
109. Moellering RE,Cornejo M,Davis TN, et al.Direct inhibition of the NOTCH transcription factor complex.Nature. 2009;462 (7270): 182-8.
110. Funahashi Y,Hernandez SL,Das I, et al.A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis.Cancer Res. 2008;68 (12): 4727-35.
111. Engin F,Bertin T,Ma O, et al.Notch signaling contributes to the pathogenesis of human osteosarcomas.Hum Mol Genet. 2009;18 (8): 1464-70.
112. Casanovas O,Hicklin DJ,Bergers G, et al.Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.Cancer Cell. 2005;8 (4): 299-309.
113. Jain RK.Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.Science. 2005;307 (5706): 58-62.
114. Miller KD,Chap LI,Holmes FA, et al.Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.J Clin Oncol. 2005;23 (4): 792-9.
115. Bagley RG,Kurtzberg L,Weber W, et al.sFLT01: a novel fusion protein with antiangiogenic activity.Mol Cancer Ther. 2011;10 (3): 404-15.
116. Fischer C,Jonckx B,Mazzone M, et al.Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.Cell. 2007;131 (3): 463-75.
117. Zaghloul N,Hernandez SL,Bae JO, et al.Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma.Int J Oncol. 2009;34 (2): 401-7.
118. Presta LG,Chen H,O'Connor SJ, et al.Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.Cancer Res. 1997;57 (20): 4593-9.
119. Ferrara N,Hillan KJ,Gerber HP, et al.Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.Nat Rev Drug Discov. 2004;3 (5): 391-400.
120. Ferrara N,Damico L,Shams N, et al.Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.Retina. 2006;26 (8): 859-70.
121. Gragoudas ES,Adamis AP,Cunningham ET, et al.Pegaptanib for neovascular age-related macular degeneration.N Engl J Med. 2004;351 (27): 2805-16.
122. Batchelor TT,Sorensen AG,Di Tomaso E, et al.AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.Cancer Cell. 2007;11 (1): 83-95.
123. Sternberg CN,Davis ID,Mardiak J, et al.Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.J Clin Oncol. 2010;28 (6): 1061-8.
124. Escudier B,Eisen T,Stadler WM, et al.Sorafenib in advanced clear-cell renal-cell carcinoma.N Engl J Med. 2007;356 (2): 125-34.
125. Mendel DB,Laird AD,Xin X, et al.In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.Clin Cancer Res. 2003;9 (1): 327-37.
126. Motzer RJ,Hutson TE,Tomczak P, et al.Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.N Engl J Med. 2007;356 (2): 115-24.
127. Kodera Y,Katanasaka Y,Kitamura Y, et al.Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.Breast Cancer Res. 2011;13 (3): R66.
128. Sawyer TK.AILERON Therapeutics.Chem Biol Drug Des. 2009;73 (1): 3-6.
129. Kalen M,Heikura T,Karvinen H, et al.Gamma-secretase inhibitor treatment promotes VEGF-A-driven blood vessel growth and vascular leakage but disrupts neovascular perfusion.PLoS One. 2011;6 (4): e18709.